VALPROIC ACID - INVITRO PLASMA-PROTEIN BINDING AND INTERACTION WITH PHENYTOIN

被引:109
作者
CRAMER, JA
MATTSON, RH
机构
[1] Epilepsv Center, Veterans Administration Medical Center, West Haven, CT
[2] Department of Neurology, Yale University School of Medicine, New Haven, CT
关键词
Binding; Interaction; Phenytoin; Valproic acid;
D O I
10.1097/00007691-197901000-00011
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Because valproic acid (VPA) is highly bound to plasma protein, several variables affecting binding will significantly alter the quantity of free drug which is pharmacologically active. Therefore, total VPA plasma concentrations do not reflect the therapeutic strength of the drug in tissue. We have performed equilibrium dialysis and ultrafiltration studies of VPA binding to plasma protein. The converging data in these in vitro studies indicate a clinically significant alteration in the percent of free VPA when total drug concentration exceeds 80 jag/ml. Saturation of drug binding sites probably occurs in this range. At 20-60 fig/ml VPA there is 5% free drug, with a significant increase to 8% free at 80 Mg/ml; free drug increases to over 20% at 145 /ttg/ml total VPA. Human plasma, which is low in albumin, has twice the quantity of free VPA as normal plasma (10 versus 5% free). The clinical evidence of interaction between VPA and phenytoin is confirmed in vitro by the increase in the free fraction of both drugs. VPA binding decreases by 3-6%, while phenytoin binding decreases 5-6% as both drugs reach high plasma concentrations. When appropriate, laboratory reports should be available defining concentration of free drug in plasma for optimal interpretation of drug concentrations relative to clinical effects. © 1979 Raven Press, New York.
引用
收藏
页码:105 / 116
页数:12
相关论文
共 21 条
  • [11] Simon D., Penry J.K., Sodium dwV-propylacetate (DPA) in the treatment of epilepsy, Epilepsia, 16, pp. 549-573, (1975)
  • [12] Gugler R., Mueller G., Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease, Br J Clin Pharmacol, 5, pp. 441-446, (1978)
  • [13] Loscher W., Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse, J Pharmacol Exp Ther, 204, pp. 255-261, (1978)
  • [14] Klotz U., Antonin K.H., Pharmacokinetics and bioavailability of sodium valproate, Clin Pharmacol, 21, pp. 736-743, (1977)
  • [15] Gugler R., Schell A., Eichelbaum M., Froscher W., Schulz H.U., Disposition of valproic acid in man, Eur J Clin Pharmacol, 12, pp. 125-132, (1977)
  • [16] Klotz U., Rapp T., Muller W.A., Disposition of valproic acid in patients with liver disease, Eur J Clin Pharmacol, 13, pp. 55-60, (1978)
  • [17] Patsalos P.H., Lascelles P.T., Effect of sodium valproate on plasma protein binding of diphenylhydantoin, J Neurol Neurosurg Psychiatry, 40, pp. 570-574, (1977)
  • [18] Patel I.H., Levy R.H., Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids, Epilepsia, 20, pp. 85-90, (1979)
  • [19] Spector A.A., Santos E.C., Ashbrook J.D., Fletcher J.E., Influence of free fatty acid concentration on drug binding to plasma albumin, Ann NY Acad Sei, 226, pp. 247-258, (1973)
  • [20] Birkett D.J., Myers S.P., Sudlow G., Effects of fatty acids on two specific drug binding sites on human serum albumin, Mol Pharmacol, 13, pp. 987-992, (1977)